Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases
Article first published online: 20 MAY 2009
DOI: 10.1111/j.1365-2249.2009.03977.x
© 2009 British Society for Immunology
Additional Information
How to Cite
Hu, C., Wong, F. S. and Wen, L. (2009), Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clinical & Experimental Immunology, 157: 181–190. doi: 10.1111/j.1365-2249.2009.03977.x
Publication History
- Issue published online: 7 JUL 2009
- Article first published online: 20 MAY 2009
- Accepted for publication 8 May 2009
- Abstract
- Article
- References
- Cited By
Keywords:
- autoimmune disease;
- B cell;
- immunotherapy
Summary
B cells play an important role in the pathogenesis of both systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce autoantibodies, but are also specialized to present specific autoantigens efficiently to T cells. Furthermore, these B cells can secrete proinflammatory cytokines and can amplify the vicious cycle of self-destruction. Thus, B cell-directed therapies are potentially an important approach for treating autoimmune diseases. On the other hand, like T cells, there are subsets of B cells that produce anti-inflammatory cytokines and are immunosuppressive. These regulatory B cell subsets can protect against and ameliorate autoimmune diseases. Thus targeting B cells therapeutically will require this balance to be considered. Here we summarize the roles of pathogenic and regulatory B cells and current applications of B cell-directed therapy in autoimmune diseases. Considerations for future development of B cell-directed therapy for autoimmune diseases have also been discussed.

1365-2249/asset/cei_left.gif?v=1&s=ffee144c532fe5e73bbb89290ba14e154b0d400b)
1365-2249/asset/cei_right.gif?v=1&s=c14d545a5215173707c8202758d5b25fd0bede44)
